<p>Innate Pharma S.A. 赞助的 ADR（纳斯达克：IPHA - 获取免费报告）在周二的午盘交易中股价上涨了 3.6%。该股票最高交易价格为 $1.7650，最后交易价格为 $1.72。在午盘交易中交易了 9,959 股，较平均交易量 21,379 股下降了 53%。该股票之前的收盘价为 $1.66。</p>
<p>获取 <strong>Innate Pharma</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>多位分析师对该股票发表了看法。BTIG Research 在 10 月 29 日的研究报告中重申了 &#34;买入&#34; 评级，并设定了 $8.00 的价格目标。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Innate Pharma 的 &#34;卖出（e+）&#34; 评级。最后，HC Wainwright 在 10 月 29 日的研究报告中设定了 $5.00 的价格目标，并给予该公司 &#34;买入&#34; 评级。一位股票研究分析师给予该股票 &#34;强烈买入&#34; 评级，一位给予 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级，另一位给予 &#34;卖出&#34; 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价格为 $5.00。</p>
<p><strong>阅读我们关于 IPHA 的最新分析</strong></p>
<h2>Innate Pharma 股价上涨 3.6%</h2>
<p>该公司的 50 日移动平均价格为 $1.75，200 日移动平均价格为 $1.91。</p>
<h2>机构投资者对 Innate Pharma 的看法</h2>
<p>多家对冲基金最近增加或减少了对 IPHA 的持股。Jane Street Group LLC 在第四季度购买了 Innate Pharma 的新头寸，价值 $162,000。Millennium Management LLC 在第四季度购买了价值 $36,000 的 Innate Pharma 新股份。最后，OLD Mission Capital LLC 在第四季度购买了约 $50,000 的 Innate Pharma 新头寸。目前，0.16% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Innate Pharma</h2>
<p>（获取免费报告）</p>
<p>Innate Pharma SA 是一家临床阶段的生物技术公司，专注于发现和开发基于抗体的疗法，利用身体的先天免疫系统对抗癌症。公司成立于 1999 年，总部位于法国马赛，开创了旨在激活自然杀伤细胞和巨噬细胞的新型单克隆抗体，为现有的免疫肿瘤治疗提供了补充方法。</p>
<p>该公司的主导项目 monalizumab 旨在靶向 NKG2A 免疫检查点受体，并与阿斯利康合作开发。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Innate Pharma</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这让我感到愤怒</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Innate Pharma 吗？</h2>
<p>在你考虑 Innate Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Innate Pharma 并不在名单上。</p>
<p>虽然 Innate Pharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IPHA

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

IBBQ

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>Innate Pharma (NASDAQ:IPHA) 的股价在午盘交易中上涨了 3.6%，达到了 1.72 美元，尽管交易量下降了 53%。分析师们的意见不一，BTIG Research 维持 “买入” 评级，目标价为 8.00 美元，而 Weiss Ratings 则给予 “卖出” 评级。该股票的平均评级为 “适度买入”，目标价为 5.00 美元。机构投资者最近增加了对该公司的持股，该公司专注于开发基于抗体的癌症治疗疗法</p>

<p>Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) shares shot up 3.6% during mid-day trading on Tuesday . The stock traded as high as $1.7650 and last traded at $1.72. 9,959 shares were traded during mid-day trading, a decline of 53% from the average session volume of 21,379 shares. The stock had previously closed at $1.66.</p>
<div class="lb-trans"><p>Innate Pharma S.A. 赞助的 ADR（纳斯达克：IPHA - 获取免费报告）在周二的午盘交易中股价上涨了 3.6%。该股票最高交易价格为 $1.7650，最后交易价格为 $1.72。在午盘交易中交易了 9,959 股，较平均交易量 21,379 股下降了 53%。该股票之前的收盘价为 $1.66。</p>
</div><p>Get <strong>Innate Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Innate Pharma</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of analysts have weighed in on the stock. BTIG Research restated a &#34;buy&#34; rating and set a $8.00 price objective on shares of Innate Pharma in a research note on Wednesday, October 29th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Innate Pharma in a research note on Thursday, January 22nd. Finally, HC Wainwright set a $5.00 price target on shares of Innate Pharma and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $5.00.</p>
<div class="lb-trans"><p>多位分析师对该股票发表了看法。BTIG Research 在 10 月 29 日的研究报告中重申了 &#34;买入&#34; 评级，并设定了 $8.00 的价格目标。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Innate Pharma 的 &#34;卖出（e+）&#34; 评级。最后，HC Wainwright 在 10 月 29 日的研究报告中设定了 $5.00 的价格目标，并给予该公司 &#34;买入&#34; 评级。一位股票研究分析师给予该股票 &#34;强烈买入&#34; 评级，一位给予 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级，另一位给予 &#34;卖出&#34; 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价格为 $5.00。</p>
</div><p><strong>Read Our Latest Analysis on IPHA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 IPHA 的最新分析</strong></p>
</div><h2>Innate Pharma Stock Up 3.6%</h2>
<div class="lb-trans"><h2>Innate Pharma 股价上涨 3.6%</h2>
</div><p>The business's 50 day moving average price is $1.75 and its 200 day moving average price is $1.91.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 $1.75，200 日移动平均价格为 $1.91。</p>
</div><h2>Institutional Investors Weigh In On Innate Pharma</h2>
<div class="lb-trans"><h2>机构投资者对 Innate Pharma 的看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in IPHA. Jane Street Group LLC purchased a new position in shares of Innate Pharma in the 4th quarter worth $162,000. Millennium Management LLC purchased a new stake in Innate Pharma during the fourth quarter valued at $36,000. Finally, OLD Mission Capital LLC bought a new position in Innate Pharma in the fourth quarter valued at about $50,000. 0.16% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>多家对冲基金最近增加或减少了对 IPHA 的持股。Jane Street Group LLC 在第四季度购买了 Innate Pharma 的新头寸，价值 $162,000。Millennium Management LLC 在第四季度购买了价值 $36,000 的 Innate Pharma 新股份。最后，OLD Mission Capital LLC 在第四季度购买了约 $50,000 的 Innate Pharma 新头寸。目前，0.16% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Innate Pharma</h2>
<div class="lb-trans"><h2>关于 Innate Pharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.</p>
<div class="lb-trans"><p>Innate Pharma SA 是一家临床阶段的生物技术公司，专注于发现和开发基于抗体的疗法，利用身体的先天免疫系统对抗癌症。公司成立于 1999 年，总部位于法国马赛，开创了旨在激活自然杀伤细胞和巨噬细胞的新型单克隆抗体，为现有的免疫肿瘤治疗提供了补充方法。</p>
</div><p>The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.</p>
<div class="lb-trans"><p>该公司的主导项目 monalizumab 旨在靶向 NKG2A 免疫检查点受体，并与阿斯利康合作开发。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Innate Pharma</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This makes me furious</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Innate Pharma</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这让我感到愤怒</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Innate Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Innate Pharma 吗？</h2>
</div><p>Before you consider Innate Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Innate Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Innate Pharma 并不在名单上。</p>
</div><p>While Innate Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Innate Pharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%  - Here's What Happened

Market Beat

Innate Pharma SA

Invesco Nasdaq Biotechnology ETF

Innate Pharma（纳斯达克股票代码：IPHA）股价上涨 3.6% - 以下是发生的事情